Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phleum pratense pollen extract enriched
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Sublingual
01
Overview
Phleum pratense pollen extract enriched is an allergen immunotherapy (AIT) developed by Inmunotek S.L. for the treatment of allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma triggered by Timothy grass pollen. The product consists of a polymerized allergen extract (allergoid) of *Phleum pratense*, modified with glutaraldehyde to reduce IgE-mediated side effects while maintaining the ability to induce T-cell tolerance. The "enriched" formulation specifically ensures high and standardized concentrations of major allergens, particularly Phl p 1 and Phl p 5, which are critical for therapeutic efficacy. By exposing the immune system to these modified allergens, the drug promotes a shift from a Th2-dominated allergic response to a Th1 and regulatory T-cell (Treg) profile, alongside the induction of allergen-specific IgG4 blocking antibodies that compete with IgE for allergen binding.
- Brand names
- ClustekOraltekAlunitekClustek Max
- Other names
- Timothy grass pollen extractPhleum pratense allergoidPolymerized Phleum pratense extract
02
Targets
EXPB1 (Group 1 beta-expansin)Group 5 grass pollen allergenPhl p (Timothy grass pollen allergen)
Beyond the preview
Go deeper on phleum pratense pollen extract enriched.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phleum pratense pollen extract enriched.